FRX Forest Road Acquisition Corp

Today, www.BollingerReport.com introduced featured coverage of Alkermes Plc (NASDAQ: ALKS) and Forest Laboratories, Inc. (NYSE: FRX). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=ALKS&sm2=FRX.

Upcoming macro-economic 'tides of influence' are buoyed by crisis both home and abroad. Spanish and Italian yields continue to climb as efforts by the European Central Bank have stopped short of establishing sovereign bond guarantees for any one country. The result is historic yields and a grave concern for the solvency of interbank lending. Markets were drawn to concerns over domestic policy stalemates producing downgrade risks. Despite the situation, there continues to be unique value and opportunity found within careful discretion.

Bollinger Report screened and selected Alkermes Plc for its current position within the healthcare industry. Alkermes plc., formerly Alkermes, Inc., is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. A copy of this report featuring Alkermes Plc (NASDAQ: ALKS) is available at: www.BollingerReport.com/index.php?sm1=ALKS.

Bollinger Report is featuring Forest Laboratories, Inc. for its changing role within the healthcare industry. Forest Laboratories, Inc. (Forest) develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. To download researches and analysis on Forest Laboratories, Inc. (NYSE: FRX) we welcome investors to visit: www.BollingerReport.com/index.php?sm2=FRX.

About Bollinger Report Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.

Contact: Martin Schwartz Email Contact www.BollingerReport.com